These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 31955136)

  • 1. A long-term follow-up of rituximab treatment in 20 Chinese patients with neuromyelitis optica spectrum disorders.
    Lu Q; Luo J; Hao H; Liu R; Jin H; Jin Y; Gao F
    Mult Scler Relat Disord; 2020 May; 40():101933. PubMed ID: 31955136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders.
    Novi G; Bovis F; Capobianco M; Frau J; Mataluni G; Curti E; Zuliani L; Cavalla P; Brambilla L; Annovazzi P; Repice AM; Lanzillo R; Esposito S; Benedetti L; Maietta I; Sica F; Buttari F; Malucchi S; Fenu G; Landi D; Bosa C; Realmuto S; Malentacchi M; Granella F; Signori A; Bonavita S; Uccelli A; Sormani MP;
    Mult Scler Relat Disord; 2019 Nov; 36():101430. PubMed ID: 31610404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability.
    Zéphir H; Bernard-Valnet R; Lebrun C; Outteryck O; Audoin B; Bourre B; Pittion S; Wiertlewski S; Ouallet JC; Neau JP; Ciron J; Clavelou P; Marignier R; Brassat D
    J Neurol; 2015 Oct; 262(10):2329-35. PubMed ID: 26194198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of rituximab treatment regime on time to relapse in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder.
    Nasir M; Hone L; Tallantyre E; Kelly P; Leite MI; Robertson N; Bestwick J; Huda S; Palace J; Dobson R
    Mult Scler Relat Disord; 2024 May; 85():105528. PubMed ID: 38479046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of low dose of rituximab compared with azathioprine in Chinese patients with neuromyelitis optica: an over 2-year follow-up study.
    Zhang M; Zhang C; Bai P; Xue H; Wang G
    Acta Neurol Belg; 2017 Sep; 117(3):695-702. PubMed ID: 28608315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study.
    Shaygannejad V; Fayyazi E; Badihian S; Mirmosayyeb O; Manouchehri N; Ashtari F; Asgari N
    J Neurol; 2019 Mar; 266(3):642-650. PubMed ID: 30635724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
    Evangelopoulos ME; Andreadou E; Koutsis G; Koutoulidis V; Anagnostouli M; Katsika P; Evangelopoulos DS; Evdokimidis I; Kilidireas C
    J Neurol Sci; 2017 Jan; 372():92-96. PubMed ID: 28017256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.
    Tahara M; Oeda T; Okada K; Kiriyama T; Ochi K; Maruyama H; Fukaura H; Nomura K; Shimizu Y; Mori M; Nakashima I; Misu T; Umemura A; Yamamoto K; Sawada H
    Lancet Neurol; 2020 Apr; 19(4):298-306. PubMed ID: 32199095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease course, progression and activity of neuromyelitis optica (NMOSD) in patients who were treated with Rituximab, 6 and 12 months after receiving the first dose of drug, in Isfahan city.
    Ashtari F; Mehdipour R; Shaygannejad V; Mansourian M
    Mult Scler Relat Disord; 2019 Sep; 34():77-82. PubMed ID: 31233958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FCGR3A-V158F gene polymorphism: A potential predictor for rituximab dosing optimization in Chinese patients with neuromyelitis optica spectrum disorder.
    Cui L; Jiao J; Zhang Y; Wang R; Peng D; Jiao Y; Zhang W
    Mult Scler Relat Disord; 2024 Jun; 86():105600. PubMed ID: 38579568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis.
    Damato V; Evoli A; Iorio R
    JAMA Neurol; 2016 Nov; 73(11):1342-1348. PubMed ID: 27668357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder.
    Ongphichetmetha T; Jitprapaikulsan J; Siritho S; Rattanathamsakul N; Detweeratham T; Prayoonwiwat N
    Sci Rep; 2024 Feb; 14(1):3503. PubMed ID: 38347079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders.
    Correa-Díaz EP; Torres-Herrán GE; Miño Zambrano JE; Paredes-Gonzalez V; Caiza-Zambrano FJ
    Mult Scler Relat Disord; 2021 Feb; 48():102683. PubMed ID: 33338945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial.
    Nikoo Z; Badihian S; Shaygannejad V; Asgari N; Ashtari F
    J Neurol; 2017 Sep; 264(9):2003-2009. PubMed ID: 28831548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dosage of rituximab in Chinese patients with neuromyelitis optica spectrum disorder.
    Lin J; Li X; Xue B; Tong Q; Chen Z; Zhu W; Li J; Xia J
    J Neuroimmunol; 2018 Apr; 317():1-4. PubMed ID: 29501080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serious safety events in rituximab-treated multiple sclerosis and related disorders.
    Vollmer BL; Wallach AI; Corboy JR; Dubovskaya K; Alvarez E; Kister I
    Ann Clin Transl Neurol; 2020 Sep; 7(9):1477-1487. PubMed ID: 32767531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder.
    Kim SH; Huh SY; Lee SJ; Joung A; Kim HJ
    JAMA Neurol; 2013 Sep; 70(9):1110-7. PubMed ID: 23897062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral CD19
    Ellrichmann G; Bolz J; Peschke M; Duscha A; Hellwig K; Lee DH; Linker RA; Gold R; Haghikia A
    J Neurol; 2019 Jan; 266(1):57-67. PubMed ID: 30377816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients.
    Radaelli M; Moiola L; Sangalli F; Esposito F; Barcella V; Ferrè L; Rodegher M; Colombo B; Fazio R; Martinelli V; Comi G
    Mult Scler; 2016 Apr; 22(4):511-9. PubMed ID: 26199350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-Dose Mycophenolate Mofetil for Treatment of Neuromyelitis Optica Spectrum Disorders: A Prospective Multicenter Study in South China.
    Huang Q; Wang J; Zhou Y; Yang H; Wang Z; Yan Z; Long Y; Yin J; Feng H; Li C; Lu Z; Hu X; Qiu W
    Front Immunol; 2018; 9():2066. PubMed ID: 30258442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.